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3-Adrenergic Receptor Subtype Signaling In
Senescent Heart
Nitric Oxide Intoxication or “Endogenous”  Blockade for Protection?
COMPLEX biochemical, pharmacologic, and physiologic
changes occur with advancing age in the myocardium.
These changes may be subtle and virtually undetectable
under resting steady state conditions, but become prominent
under stressful stimulation. In this issue of ANESTHESIOLOGY,
Birenbaum et al.1 provide evidence for impaired inotro-
pic response (approximately 30%) to -adrenergic stim-
ulation in aged versus young rat hearts. Apart from
1-adreneric receptor (AR) down-regulation, they fur-
ther demonstrate that increased formation of nitric oxide
deriving from neuronal nitric oxide synthase (nNOS) via
the activated 3-AR subtype signaling pathway is respon-
sible for the reduced inotropy in senescent hearts.
Since the late 1980s, it is known that three -AR
subtypes, namely the 1-, 2-, and 3-AR, participate in
the regulation of cardiovascular function. Expression of
3-ARs in human hearts was first reported in 1996 by
Gauthier et al.2 The 3-AR shares only approximately
50% homology with 1/2-ARs and is particular in certain
aspects (table 1). First, in contrast to 1/2-ARs (monoex-
onic genes), the gene encoding this receptor on chro-
mosome 8 contains two exons and one intron enabling
alternative splicing and formation of two different recep-
tor isoforms with different pharmacologic properties.3
Second, the 3-AR lacks phosphorylation sites for G
protein–coupled receptor kinase and protein kinase A in
the cytoplasmic C-terminus tail, and thus is resistant to
catecholamine-induced desensitization.4 Third, besides
the strong lusitropic effects, the majority of studies sug-
gest inhibition of cardiac contractility after 3-AR stimu-
lation. Hence, in the presence of labetalol or prazosin
plus nadolol, i.e., - plus 1/2-AR blockade, norepineph-
rine becomes cardiodepressive.5 In cardiomyocytes (fig.
1), 3-ARs activate, through a pertussis toxin–sensitive Gi
protein–coupled mechanism, endothelial nitric oxide
synthase (eNOS or NOS3), located between sarcolemmal
and T-tubular caveolae, and nNOS (or NOS1), located in
the sarcoplasmic reticulum (or sarcolemma in the failing
heart), and exert nitric oxide–mediated negative inotro-
pic effects via the guanylyl cyclase–cyclic guanosine
monophosphate pathway on L-type Ca2 channels and
on myofilaments.5–8 Nitric oxide further inhibits con-
tractility by S-nitrosylation of key proteins of the respi-
ratory chain,9 energy metabolism,10 contractile appara-
tus, and Ca2 handling, and it potentiates the inhibitory
effect of the Gi protein on protein kinase A by activating
phosphodiesterase II,11 thereby reducing the second
messenger cyclic adenosine monophosphate of the Gs-
coupled 1/2-ARs. A last feature of the 3-AR is its low
expression in healthy myocardium with a preference in
left ventricular tissue, while its expression is reported to
increase by two to three times in various pathologic
conditions including sepsis,12 diabetes,13 and heart fail-
ure14 and, as shown in the current study by Birenbaum
et al.,1 during the aging process.
In perioperative medicine, the sympathetic nervous
system plays an important role in the pathogenesis of
cardiovascular complications.15 Therefore, gaining con-
trol over the adrenergic activity represents a core task in
anesthetic practice.16,17 On the other side, sustained
activation of the sympathetic nervous system with en-
hanced -AR signaling plays an important role in cardio-
vascular aging by promoting inflammation, oxidation
and nitrosylation of key proteins, and cell death.18 Con-
sistent with the free radical theory of aging, previous
studies showed increased formation of reactive oxygen
and nitrogen species in aged myocardium, mainly gen-
erated by mitochondria and nitric oxide synthase (NOS)
isoforms.19 Nitric oxide is produced by nearly all cell
types in the heart, and is synthesized from L-arginine by
the catalytic reaction of the three different highly com-
partmentalized isoforms of nitric oxide synthase (neuro-
nal or type 1 NOS [nNOS or NOS1], inducible or type 2
NOS [iNOS or NOS2], and endothelial or type 3 NOS
[eNOS or NOS3]).20 In the aged heart, iNOS and nNOS,
mainly found in cardiomyocytes and autonomic nerves,
are up-regulated, whereas eNOS, primarily expressed in
endothelial cells (but also myocytes), is down-regulated.21,22
In the adult heart, nitric oxide regulates cardiac biology
by affecting energy metabolism, substrate utilization, ap-
optosis, hypertrophy, regeneration, and precondition-
ing.23 However, its biologic effects are often “double-
edged,” with a variety of opposing effects depending on
the dose and site of action within the cell. Li et al.24
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demonstrated the deleterious effects of nitric oxide de-
rived from up-regulated iNOS in isolated perfused aged
versus young rat hearts. These authors found increased
nitric oxide and peroxynitrite formation deriving from
up-regulated iNOS, which aggravated postischemic car-
diac dysfunction and enlarged infarct size under -AR
stimulation with isoproterenol in aged versus young
hearts. nNOS expression was also increased in aged
hearts in that study, but its contribution to isoproterenol-
induced postischemic damage was not investigated.
Nonetheless, this study provides evidence that a pheno-
typic change of NOS isoforms in aged hearts may pre-
dispose to increased myocardial damage under sympa-
thetic tone. As can be speculated from the results by
Birenbaum et al.,1 the observed detrimental effect in the
study of Li et al.24 may be well explained by upregula-
tion of 3-ARs. Augmented cardiac nitric oxide formation
by 3-AR signaling was also reported to be deleterious in
sepsis, where the release of endogenous inflammatory
mediators such as tumor necrosis factor  and interleu-
kin 1 dramatically decrease the responsiveness of car-
diomyocytes to catecholamines.12 Interestingly, this re-
fractoriness to catecholamines is absent in septic 3-AR
knockout mice.12 In contrast to the toxic effects of
3-AR signaling in certain conditions, in healthy adult
hearts, 3-AR signaling is necessary to counteract the
proarrhythmogenic, and otherwise unchained chrono-
tropic, dromotropic, and inotropic effects of 1/2-ARs.
8
This phylogenetically highly conserved and protective
negative feedback loop against catecholamine toxicity is
important for a balanced and fine-tuned contractility.8
Generally speaking, 3-AR signaling acts as a countervail-
ing “brake” against adrenergic overstimulation compara-
ble with an “endogenous”  blockade. This concept is
further supported by the fact that 3-ARs maintain car-
diac sympathovagal balance by reinforcing vagal tone.
Beyond these benefits, but in contrast to pure  block-
ade, nitric oxide from 3-AR signaling further exerts
coronary and peripheral vasodilatation, and may have
“pleiotropic” effects on cardiac stem cell biology25 and
the prevention of arteriosclerosis.26 Indeed, the “phar-
macologic profile” of 3-AR signaling strongly reminds of
the one observed with the novel third-generation
-blocker nebivolol, which promotes nitric oxide forma-
tion.27 Research in the field of heart failure also supports
the idea that 3-AR signaling is beneficial rather than
detrimental. In the failing heart, the 3-AR response is
preserved even under sustained activation of the adren-
ergic system and thus antagonizes catecholamine toxic-
ity. However, this does not exclude that adverse effects
do occur from 3-AR–mediated negative inotropy, par-
ticularly during the progression of heart failure. Interest-
ingly, 3-AR knockout mice show increased SERCA2a
expression and phospholamban phosphorylation result-
ing in enhanced SERCA2a activity.28 Hence, one could
speculate that 3-AR blockade could play a salutary role
in the therapy of heart failure, at least at later stages of
the disease. Together, the biologic consequences of en-
hanced 3-AR signaling range from “nitric oxide intoxi-
cation” on one side to protection comparable to some
sort of “physiologic” or “endogenous” -blockade on the
other side. Although the study by Birenbaum et al.1
Table 1. -Adrenergic Receptor Subtype Characteristics
Receptor subtype
Main signaling components
Location Effector cells Predominant effects
Relative receptor density
in left ventricle, %
1 70–80
Gs Cardiac myocytes Increases heart rate
Postsynaptic Increases contractility
Increases relaxation
2 20–30
Gs/Gi Cardiac myocytes Increases heart rate
Presynaptic and postsynaptic Increases contractility
Increases relaxation
Peripheral and coronary vascular
smooth muscle cells
Vasodilation
Bronchiolar smooth muscle cells Bronchodilation
3 2
Gi/NO Cardiac myocytes Decreases heart rate
Decreases contractility
Increases relaxation
Gs Peripheral and coronary vascular
smooth muscle cells
Vasodilation
Presynaptic and postsynaptic
Gi and Gs  inhibitory and stimulatory G-protein regulating adenylyl cyclase; NO  nitric oxide.
Based on references 8, 15, 34, and 35.
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shows undesirable short-term effects of enhanced
3-AR signaling on inotropy in aged hearts, the bio-
logic (long-term) consequences of this pathway re-
main elusive.
A number of important questions need to be addressed
in future studies before we can translate the findings of
Birenbaum et al. to the clinical arena. First, based on
genome-wide transcriptional profiling, the molecular
mechanisms involved in reduced -adrenergic respon-
siveness in the aged heart seem to be more complex and
not just confined to a single signaling pathway. Accord-
ingly, Dobson et al.29 reported up-regulation of 19 tran-
scripts involved in age-related antiadrenergic activity,
including adenosine A1, muscarinic M3, and nicotinic 3
acetylcholine receptors, and many more. Second, female
tissue was reported to express less 3-ARs,
30 and nitric
oxide is differentially regulated in male and female
hearts, as evidenced in nNOS knockout mice, where
males develop more pronounced cardiac remodeling
than females.31 Therefore, sex-based differences may be
of relevance in 3-AR and nitric oxide signaling, specif-
ically in aged hearts. Third, although the rat and human
3-AR share 79% identity, there are pronounced hetero-
geneous pharmacologic profiles of 3-AR agonists/antag-
onists between different species. Therefore, caution
must be applied in extrapolating data obtained from rat
hearts to human myocardium. Finally, 3-ARs are also
expressed in vessels. Namely, 3-ARs are expressed on
the endothelium of coronary microarteries,32 but their
role in ischemia–reperfusion is unknown, and it is un-
clear, to date, whether vascular 3-ARs are similarly up-
regulated during the aging process.
Modulation of 3-AR signaling in the diseased heart in
general and in the senescent heart in particular opens
new therapeutic approaches. However, much research
is required to fully understand the complexity of -AR
biology with its contrasting influences. New compounds
with 3-AR agonistic and/or antagonistic properties
could help to better modulate and control the adrenergic
system in the perioperative period. For example, in cor-
onary artery bypass graft surgery patients, there is
1/2-AR but not 3-AR dysfunction after cardiopulmonary
bypass, and 3-AR stimulation could increase graft flow,
decrease oxygen consumption, and thus protect the
heart. However, these effects must be carefully balanced
against the negative inotropy of 3-AR signaling. Inter-
estingly, the single nucleotide polymorphism of the
3-AR at codon 64 from tryptophan to arginine was
found to be associated with insulin resistance, diabetes,
obesity, and hypertension.8 Hence, patient studies inves-
tigating the impact of -AR genomics on cardiac biology
and clinical outcome might help to discern the therapeu-
tic potential of 3-AR signaling in the context of other
important adrenergic polymorphisms33 in human heart
disease. Clearly, the findings by Birenbaum et al.1 are
important and will stimulate future research aiming at
improving the cardiovascular management of elderly sur-
gical at-risk patients. In this challenging endeavor, how-
ever, we need to expand our understanding of complex
-AR signaling beyond the platitude that “it is not by the
gray of the hair that one knows the age of the heart”
(Robert Bulwer-Lytton).
Fig. 1. Interrelation between 3-adrenergic receptor (AR) and the
major sympathetic and parasympathetic signaling pathways in
cardiomyocytes. In the inotropic1- and2-AR signaling path (red
arrows) protein kinase A (PKA) coordinates (1) positive inotropy
by increasing intracellular Ca2 (stimulation by phosphorylation
of the L-type Ca2 channel, of the sarcoplasmatic reticulum [SR]
Ca2 pump SERCA directly and indirectly by relieving its repres-
sion by phospholamban [PLN], and of the sarcoplasmatic retic-
ulum Ca2 release channel [RYR]); (2) positive lusitropy by
removing cytoplasmic Ca2 via the Na–Ca2 exchanger and
decreasing the affinity of Ca2 binding to Ca2 binding tro-
ponin subunit (TNC) by phosphorylation of inhibitory tro-
ponin subunit (TNI); (3) negative adrenergic feedback by
desensitization of 1-ARs (phosphorylation by PKA and G
protein–coupled receptor kinase [GRK]); and (4) stimulation
of adenosine triphosphate production in the mitochondria
by Ca2. 3-AR signaling (blue arrows) counterbalances the
canonical 1- and 2-AR path via Gi and nitric oxide (NO)
production as well as by enhancing the vagal tone by facili-
tation of acetylcholine (AcC) release from the parasympa-
thetic nerve terminals acting through the muscarinic acetyl-
choline receptor 2 (M2). Norepinephrine (NE) release from
the sympathetic nerve terminals exerts a second negative
feedback loop. Arrows denote stimulation, and blunted ends
denote inhibition. AC  adenylyl cyclase; DAG  diacylglyc-
erol; GC  soluble guanylyl cyclase; Gi and Gs  inhibitory
and stimulatory G-protein  subunits; L  L-type slow Ca2-
channel; NOS  nitric oxide synthase; PDK  3-phosphoino-
sitide–dependent kinase; PI3K  phosphoinositide-3 kinase;
PKA, PKB, PKC, and PKG  target-specific Ser/Thr protein
kinases; PLC  phospholipase C; PNT  parasympathetic
nerve terminal; SNT  sympathetic nerve terminal; Z  sar-
comeric Z disc.
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